ClinicalTrials.gg
CompletedNCT00810836Updated Sep 16, 2013

Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active Rheumatoid Arthritis

A Phase 2 interventional study of BG00012 and BG00012 in Rheumatoid Arthritis, sponsored by Biogen. Completed at 25 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-09-16.

Sponsored by Biogen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
153
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Arthritis, Rheumatoid by Biogen — none open to participants now, none under way, none of them phase 3. Arthritis, Rheumatoid · Biogen.

Enrollment
4th of 10
153 · median 94
Started
2008
with 1 other
Phase 2
10 of 16
none open now
Registered
9th of 16
by date

Among the 16 studies in Arthritis, Rheumatoid by Biogen, this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2008, is one of 10 in phase 2, and was the 9th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 16 studies in Arthritis, Rheumatoid by Biogen is open now. The open studies under Arthritis, Rheumatoid, anywhere →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Arthritis, Rheumatoid by Biogen as a file.
02

Study summary

The purpose of this study is to investigate whether the drug BG00012 can improve the symptoms of rheumatoid arthritis (RA) in patients who are already taking methotrexate for RA, but who still suffer symptoms of RA. The purpose is also to ensure that the combination of methotrexate is safe for patients to take and that any side effects are acceptable to patients with RA.

Read the detailed description

The study is a double-blind, placebo-controlled study of BG00012 plus methotrexate, versus methotrexate alone, in patients with active RA, who have had an incomplete response to other conventional disease modifying anti-rheumatic (DMARD) therapy.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • must be taking methotrexate
  • inadequate response to at least one conventional DMARD
  • swollen and tender joint count

Exclusion criteria

Exclusion Criteria:

  • previous treatment with TNF or any other biologic or prosorba column

Other criteria also apply.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
153 participants (actual)

Study arms

  • Active comparator
    1

    BG00012 480 mg/day

    Drug: BG00012

  • Active comparator
    2

    BG00012 720 mg/day

    Drug: BG00012

  • Placebo comparator
    3

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. The primary objective is the proportion of subjects with ACR20 response in their RA at Week 12.

    Time frame: 12 weeks

Secondary outcomes

  1. To determine the safety and tolerability of BG00012 with methotrexate in this population.

    Time frame: 12 weeks

07

Study locations

25 sites
  • Research Site
    Woolloongabba, Queensland 4102, Australia
  • Research Site
    Woodville, South Australia 5011, Australia
  • Research Site
    Sarnia, Ontario N7T4X3, Canada
  • Research Site
    New Market, Canada
  • Research Site
    Ottawa, Canada
  • Research Site
    Rothesay, Canada
  • Research Site
    Active, not recruiting, Czech Republic
  • Research Site
    Pardubice, Czech Republic
  • Research Site
    Uh. Hradiste, Czech Republic
  • Research Site
    Zlin, Czech Republic
  • Research Site
    Bangalore, India
  • Research Site
    Hyderabaad, India
  • Research Site
    Hyderabad, India
  • Research Site
    Lucknow, India
  • Research Site
    Bialystock, Poland
  • Research Site
    Grodzisk Mazowiecki, Poland
  • Research Site
    Lublin, Poland
  • Research Site
    Poznan, Poland
  • Research Site
    Torun, Poland
  • Research Site
    Warsaw, Poland
  • Research Site
    Warszawa, Poland
  • Research Site
    Banska Bysterica, Slovakia
  • Research Site
    Bratislava, Slovakia
  • Research Site
    Kosice, Slovakia
  • Research Site
    Piestany, Slovakia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Feb 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2008
First posted
Dec 18, 2008
Start
Dec 2008
Primary completionActual
Feb 2010
CompletionActual
Mar 2010
Last update
Sep 16, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00810836
Lead sponsor
Biogen
First posted
Dec 18, 2008
Start date
Dec 2008
Primary completion
Feb 2010
Completion
Mar 2010
Last update
Sep 16, 2013

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dimethyl Fumarate

Start the discussion